摘要
目的研究吉非替尼联合三维适形放疗治疗老年局部晚期非小细胞肺癌(NSCLC)的疗效及对血清标志物的影响。方法选取2013年6月~2015年2月在我院接受治疗的54例老年局部晚期NSCLC患者,随机分为接受吉非替尼联合三维适形放疗的观察组27例、接受三维适形放疗的对照组27例。评价治疗的近期疗效、远期疗效,测定血清肿瘤标志物的含量及毒副反应。结果观察组患者的总有效率、疾病控制率分别为85.19%、59.26%,均明显高于对照组的59.26%、29.63%(χ^2/P=4.523/0.033、4.800/0.028);观察组患者的PFS、OS分别为(17.96±5.95)个月、(44.78±10.71)个月,均明显高于对照组的(11.37±4.28)个月、(37.33±11.00)个月,PFS的生存曲线及OS的生存曲线均明显优于对照组(P<0.05);两组治疗后的血清癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)含量均明显降低,且观察组治疗后的血清CEA、CYFRA21-1含量均明显低于对照组(P<0.05)。两组患者毒副反应发生率比较,差异无统计学意义(P>0.05)。结论吉非替尼联合三维适形放疗治疗老年局部晚期NSCLC能够取得较三维适形放疗更为优越的疗效。
Objective To research the efficacy of gefitinib combined with three-dimensional conformal radiotherapy(3D-CRT)for elderly patients with locally advanced non-small cell lung cancer(NSCLC)and its impact on serum markers.Methods A total of 54 elderly patients with locally advanced NSCLC admitted to our hospital from June 2013 to February 2015 were selected,and they were randomly divided into the observation group(n=27)and the control group(n=27).The observation group was treated with gefitinib combined with 3D-CRT,while the control group was treated with 3D-CRT.The short-term and long-term therapeutic efficacies were evaluated,and the contents of serum tumor markers and side effects were determined.Results The total effective rate and the disease control rate were 59.26%and 85.19%in the observation group,which were significantly higher than 29.63%and 59.26%,respectively in the control group(χ^2/P=4.800/0.028,4.523/0.033).The progression free survival(PFS)and the overall survival(OS)were(17.96±5.95)months and(44.78±10.71)months in patients of the observation group,which were significantly higher than(11.37±4.28)months and(37.33±11.00)months,respectively in patients of the control group.The survival curves of PFS and OS in the observation group were significantly superior to those in the control group(P<0.05).The levels of serum carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)in the two groups after treatment were significantly decreased,and the levels of serum CEA and CYFRA21-1 in the observation group after treatment were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of side effects between the two groups(P>0.05).Conclusion Gefitinib combined with 3D-CRT.can achieve superior therapeutic efficacy than 3D-CRT.alnoe for elderly patients with locally advanced NSCLC.
作者
林丽平
谢学军
郭玛丽
LIN Liping;XIE Xuejun;GUO Mali(Department of Internal Medicine-Oncology,Sanming First Hospital Affiliated to Fujian Medical University,Fujian,Sanming 365000,China)
出处
《中国医药科学》
2020年第24期201-204,共4页
China Medicine And Pharmacy
关键词
局部晚期非小细胞肺癌
吉非替尼
三维适形放疗
肿瘤标志物
Locally advanced non-small cell lung cancer
Gefitinib
Three-dimensional conformal radiotherapy
Tumor marker
